The typical example of insider trading looks something like this: An employee finds out her company is about to be acquired and buys its stock before the deal is announced. But what if the employee buys a rival company’s stock on the theory it, too, will rise?
That’s the question at stake in a trial that kicks off March 25 in San Francisco, where the US Securities and Exchange Commission is accusing a former biopharmaceutical executive of illegally trading a competitor’s stock.
Securities traders and lawyers are closely watching the case, the SEC’s first attempt to pursue so-called shadow trading. ...